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It is a privilege and an honor to be asked to present a general overview and a his-
torical perspective of a subject that has occupied the last 20 years of my medical
career. I can assure you that when I accepted this assignment, I did not regard it with
a "jaundiced eye." It is particularly appropriate to discuss viral hepatitis with
military consultants to the Armed Forces because it is well known that this disease
has had a profound effect on military as well as civilian populations throughout the
world.
During the past three or more centuries "epidemic jaundice" (viral hepatitis, type
A) has been recognized as an important military disease, especially during periods of
war. Outbreaks were recorded in Germany in 1629 and in the British Army in
Flanders in 1743. Epidemics occurred in military and civilian populations at the time
of the siege of Paris during the Franco-Prussian war in 1870. Other epidemics oc-
curred during the Boer War in South Africa and in the Japanese Navy during the war
with Russia in 1904. This trend continued during the course of all subsequent
conflicts: World Wars I and II, the Middle East Wars in 1948, 1956, and 1967, and
more recently the Korean and Vietnamese Wars.
During the past 50 years the term "epidemic jaundice" referred to a disease that
had other names in various parts of the world: jaunice des camps in France, Solda-
tengelbsucht in Germany, infective hepatitis in England, Botkin's disease in Russia,
and acute catarrhal jaundice, epidemic hepatitis, and infectious hepatitis in the
United States and other parts of the world. More recently the term proposed by
MacCallum in the 1940's, "viral hepatitis, type A," has been adopted.
Unlike epidemic jaundice, an ancient disease, serum hepatitis (type B hepatitis)
has a more recent history. The first outbreak was described less than 100 years ago
by Liirman (1). The occurrence ofsmallpox in Bremen in 1883 was followed by an ex-
tensive vaccination program. The vaccine at that time was prepared from glycer-
inated lymph of human origin. Of 1289 vaccinated shipyard workers, 191 (15%)
developed jaundice after intervals of several weeks to 6 months. In contrast, of 500
unvaccinated new employees, none becamejaundiced. In retrospect, it is obvious to-
day that Liirman's report of an epidemic of icterus in 1883 represented the first
recognition ofan epidemic ofviral hepatitis, type B.
During the first half of this century it became obvious that epidemics ofjaundice
were occurring in patients attending venereal disease clinics, diabetic clinics, and tu-
berculosis clinics, and in children who received inoculations of measles and mumps
human convalescent serum, in patients who received blood transfusions, and in
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military personnel who received yellow fever vaccine. Epidemiological investigations
incriminated contaminated needles and syringes, contaminated blood and blood
products, and the infectious human serum component of the vaccine as the source of
hepatitis virus. The disease that has been designated as viral hepatitis, type B, today,
accumulated more than 20 aliases during the past 50 years. A few of the more com-
mon former names include serum hepatitis, long-incubation hepatitis, post-transfu-
sion hepatitis, homologous serum hepatitis or jaundice, yellow fever vaccine hepa-
titis, and post-salvarsan or arsphenamine hepatitis orjaundice.
In his discussion of historical perspectives at an international symposium on viral
hepatitis that was held in Toronto, Canada, in 1971, Dr. F. 0. MacCallum cited two
important events related to hepatitis that undoubtedly had an impact on both the his-
tory of medicine and the history of the world (2). The first event occurred in Sweden
in 1925 and the second in England in 1942.
A report by Flaum and colleagues (3) from Sweden described an epidemic ofjaun-
dice that occurred among diabetics attending a laboratory for blood tests. This epi-
sode occurred shortly after Banting and Best in Toronto isolated insulin. Fortu-
nately, the Swedish patients did not receive insulin. As stated by Dr. MacCallum,
"one can imagine the consternation that might have been caused iftheirhepatitis had
occurred after injection of the new wonder drug and the present world-wide rapid
dissemination ofinformation in the lay and medical press had prevailed at that time."
The episode that occurred in England is best described in Dr. MacCallum's own
words: "One day in 1942, I received a message to go to Whitehall to see one of the
senior medical advisers and when I arrived I was asked 'What is this yellow fever
vaccine and how dangerous is it?' After explaining its constitution and the possibility
of a mild reaction four to five days after inoculation, I was told that the Cabinet was
at that moment debating whether or not Mr. Churchill should be allowed to go to
Moscow, which he wished to do in a few days' time. The yellow fever vaccine was
theoretically essential before he could fly through the Middle East, but I explained
that no antibody would be produced before seven to ten days so that there would be
little point in giving the vaccine. It was finally decided that the vaccine would not be
used, and the administrators would take care ofthe situation. Several months later I
received an irate call from the Director of Medical Services of the R.A.F. who had
been inoculated with the same batch ofvaccine which would have been used for Mr.
Churchill, and was informed that the D. G. had spent a very mouldy Christmas with
hepatitis about 66 days after his inoculation.... I will leave it to you to speculate on
what might possibly have been the effect on the liver of our famous statesman and
our ultimate fate ifhe had received the icterogenic vaccine."
The importance ofhepatitis as a military and civilian disease provided the motiva-
tion for many investigators in the 1940's to search for a suitable animal model for the
propagation of the causative agent or agents. With the advent of tissue culture
technology in the 1950's it was hoped that hepatitis virus, like poliovirus and other
viruses, would be successfully cultivated in cell culture.
On March 31, 1954, a symposium on the laboratory propagation and detection of
the agent of hepatitis was sponsored by the National Academy of Sciences and the
Armed Forces Epidemiological Board. The participants, several ofwhom are present
at this meeting, reviewed the extensive studies by many investigators who described
negative results of their attempts to propagate hepatitis virus in cell cultures, in
guinea pigs, in hamsters, in rabbits, in various strains of mice and rats, in newborn
swine, and in such nonhuman primates as baboons, chimpanzees, marmosets, and
various species of monkeys. At the conclusion of this meeting Dr. Sabin who was
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present stated that he considered the meeting unique in presenting such an encourag-
ing display ofperseverance and patience in the faceoffrustrating experimentation.
Two and a half years later another symposium, sponsored by Henry Ford Hos-
pital, was held in Detroit, Michigan. The participants ofthis symposium reviewed the
current status of knowledge of the etiology of viral hepatitis. At this meeting
McLean, Rightsell, and their colleagues (4) described their studies suggesting that
they had cultured hepatitis virus in Detroit: six cell cultures. In their conclusion they
stated that, "On the basis of these data we cannot be sure that the virus ofhepatitis is
being cultivated, but it is not unlikely and certainly further work is indicated."
Nearly 20 years have elapsed since this meeting and as of the present time no one has
successfully cultivated hepatitis virus A or B in cell culture.
Evidence for the viral etiology of hepatitis stemmed in great part from the results
of experiments with human volunteers in the 1940's. Type A hepatitis was studied by
Voeght (5), by Cameron (6), by MacCallum and Bradley (7), by Havens (8), by Paul,
Havens, Sabin, and Philip (9), and by Stokes and Neefe (10). These investigators also
studied type B hepatitis (9,11). These studies identified two immunologically distinct
types of hepatitis. Type A hepatitis was characterized by an incubation period of ap-
proximately 15 to 34 days as compared with 56 to 134 days for type B. Type A hepa-
titis occurred after oral and parenteral exposure. Type B hepatitis, however, was
transmitted by inoculation but not orally. Homologous immunity was present, and
there was no evidence of heterologous immunity. Hepatitis A virus was present in
stools and serum during the acute phase of the disease; it was not detected during
convalescence. Hepatitis B virus was demonstrated in blood during the incubation
period as well as the acute phase of the disease. These studies were extended by
Stokes and colleagues (12) in the 1950's when they demonstrated a carrier state.
It was in 1945 that Stokes and Neefe (13) and Havens and Paul (14) reported that
type A hepatitis could be prevented or attenuated by the use of 'y-globulin. These
studies were subsequently confirmed and extended by many other investigators.
Passive immunization will be discussed in detail by Major Gilbert Irwin during the
course of this symposium.
Our studies at the Willowbrook State School in the late 1950's and 1960's further
confirmed and extended previous observations of the natural history, epidemiology,
and prevention of viral hepatitis. The background of our studies and the justification
for carrying them out were described in detail in various publications (15-18). The
new findings may be summarized as follows.
(i) Hepatitis A virus was demonstrated in stools and serum during the latter part
of the incubation period as well as during the acute phase; it was not detected during
convalescence.
(ii) Serum containing hepatitis B virus was shown to be infective by mouth as well
as by inoculation.
(iii) Hepatitis B was shown to spread under the conditions of prolonged, intimate
physical contact.
(iv) Two immunologically distinct types of hepatitis were identified in an institu-
tion where hepatitis was highly endemic. One type, designated MS-1, resembled type
A hepatitis, and the other, designated MS-2, resembled type B hepatitis.
(v) A series of controlled studies with immune serum globulin confirmed and
extended previous reports (19,20). These studies provided the basis for recommenda-
tions for the use and dosage schedule of y-globulin for military personnel assigned to
areas where hepatitis was highly endemic. They were subsequently confirmed by the
Korean studies to be discussed by Major Irwin.
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The discovery of Australia antigen by Blumberg and his colleagues (21,22) during
the latter part of the 1960's and its association with hepatitis B virus provided the
technology needed to further clarify the natural history of type B hepatitis. During a
seminar on viral hepatitis in Paris in 1971 Dr. John F. Enders highlighted this im-
portant development when he said: "After a long and arid period, a new and exhila-
rating phase in the study of hepatitis has begun. The discovery of Australia antigen
came like an unexpected shower on desert soil." In the wake of this discovery, many
investigators from many disciplines, virology, epidemiology, immunology, bio-
chemistry, hematology, and others, were attracted to the field of hepatitis research.
The result has been a virtual explosion ofnew knowledge.
The exciting new developments in both hepatitis B and hepatitis A research were
discussed in March of this year during a 3-day symposium sponsored by the National
Academy ofSciences (23). Briefly, the highlights ofthis symposium included:
(i) Visualization by electron microscopy and partial characterization ofhepatitis A
virus, its successful transmission to marmoset monkeys and chimpanzees, and the
development of a practical, sensitive immune adherence test to detect hepatitis A an-
tibody by Dr. Hilleman and his colleagues.
(ii) Visualization by electron microscopy and characterization of hepatitis B virus
and its antigens, its successful transmission to chimpanzees, the development of
sensitive tests to detect hepatitis B surface and core antigens and their respective an-
tibodies, the development of an inactivated hepatitis B vaccine from purified hepatitis
B surface antigen, and the development of hepatitis B immune serum globulin from
plasma containing high levels of antibody to hepatitis B surface antigen. These new
developments will be summarized and updated by the participants of this symposium.
I should like to conclude this overview and historical perspective of viral hepatitis
on a note of serendipity. It is well known that Blumberg's study that led to the dis-
covery of Australia antigen was not designed to discover the causative agent of type
B hepatitis. If he had included this objective in his grant application, the study section
would have considered him either naive or out of his mind. Yet, the chance inclusion
of one serum specimen from an Australian aborigine in a panel of 24 sera that was
used in his study of polymorphisms of serum proteins and the development of iso-
precipitins in transfused patients led to detection of an antigen that subsequently
proved to be the hepatitis B surface antigen. In retrospect, it was obvious that the
Australian aborigine was a hepatitis B carrier.
Our development of a heat-inactivated hepatitis B vaccine in 1970 also resulted
from pure serendipity. Our study was designed to determine the effect of heat (boil-
ing for 1 min) on the infectivity of hepatitis A virus. The results indicated that this
treatment of a 1:10 dilution of MS-I serum in distilled water destroyed the infectivity
of the hepatitis A virus that was present (24). These findings indicated that it was not
necessary to boil water for 15 to 20 min under field conditions where hepatitis
contamination was suspected. Later when the same study was repeated using a 1:10
dilution of MS-2 serum in distilled water, it became obvious that the 1-min boil
destroyed the infectivity of the hepatitis B virus, but much to our surprise the ma-
terial was antigenic. In subsequent studies it was shown that this heat-inactivated
serum was antigenic, protective, and not infectious and that it behaved like an inacti-
vated hepatitis B vaccine (25,26).
During the past 5 years progress achieved in hepatitis research has been truly
phenomenal. However, as we shall learn during the course of this symposium much
remains to be done. Unlike the difficult problem ofcancer the technology is available,
in great part, to solve many problems related to hepatitis. At least two important in-
gredients are essential: money and time. We who have been involved in hepatitis re-
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search during the past three decades have been keenly aware that until recent years
the major support came from the Armed Forces. Our studies on the natural history
and prevention of viral hepatitis have been funded by the Army for 21 consecutive
years. A recent survey by Dr. Sabin revealed that in 1974 the National Institutes of
Health provided the major support to most investigators in the field. Additional funds
have been provided by other governmental as well as private agencies. I feel confi-
dent that in his closing remarks Dr. Sabin will highlight the urgent need for continua-
tion ofadequate support at this crucial period when so many problems need solution.
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